|
MechanismH1 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Canada |
First Approval Date31 Dec 1991 |
|
MechanismH1 receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Double-Blind, Randomized, Placebo-Controlled, Cross-Over, Allergen Challenge Study to Evaluate Taste and Local Tolerance of NLA Nasal Spray in Patients With Allergic Rhinitis
Evaluation of NLA Nasal Spray with regard to taste perversion and local tolerance
/ Not yet recruitingNot Applicable A double blind, randomized, cross-over, placebo controlled study, evaluating the time-to-onset of action of BLX000441-002 nasal spray in healthy volunteers. - Time to Onset
100 Clinical Results associated with Biolipox AB
0 Patents (Medical) associated with Biolipox AB
100 Deals associated with Biolipox AB
100 Translational Medicine associated with Biolipox AB